Determination of the optimal volume of ascitic fluid for the precise diagnosis of malignant ascites

被引:14
作者
Zhang, Feifei [1 ]
Feng, Zhenning [1 ]
Zhang, Yichi [1 ]
Liu, Zishuai [1 ]
Sun, Xiaoli [1 ]
Jin, Shizhu [1 ]
机构
[1] Harbin Med Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 2, Harbin 150086, Heilongjiang, Peoples R China
关键词
Diagnosis of malignant ascites; negative predictive value; optimal volume; paraffin-embedded cell blocks; sensitivity; TUMOR-MARKERS; DIFFERENTIAL-DIAGNOSIS; PLEURAL FLUID; MANAGEMENT; PATHOPHYSIOLOGY; PARACENTESIS; ACCURACY; CYTOLOGY; EFFUSION; BENIGN;
D O I
10.4103/sjg.SJG_547_18
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The aim of this study was to determine the optimal volume of peritoneal effusion required to diagnose malignant ascites. Patients and Methods: The authors recruited 123 patients with shifting dullness and obtained 123 peritoneocentesis fluid samples. The samples were divided into seven aliquots of 10, 50, 100, 150, 200, 250, and 300 mL for cytopathological examination. The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were calculated for each aliquot. Results: The sensitivity for the diagnosis of malignant ascites gradually increased as the sample volume increased and reached a constant value at a volume of 200 mL. The sensitivity and NPV for the 10-, 100-, and 150-mL volumes were significantly different from those for the 200-mL sample. However, the sensitivity and NPV for the 250- and 300-mL volumes were not significantly different. The sensitivity for the diagnosis of malignant ascites is closely related to the volume of peritoneal fluid that is extracted by peritoneocentesis. Conclusion: We suggest a volume of 200 mL as the optimal minimum volume to confirm alignant ascites in patients with shifting dullness.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 25 条
  • [1] Drawing the line: Differentiating transudates from exudates
    Antony, VB
    [J]. RESPIRATION, 2002, 69 (03) : 198 - 198
  • [2] Malignant ascites - New concepts in pathophysiology, diagnosis, and management
    Aslam, N
    Marino, CR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (22) : 2733 - 2737
  • [3] Malignant ascites: Systematic review and guideline for treatment
    Becker, G
    Galandi, D
    Blum, HE
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (05) : 589 - 597
  • [4] Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
    Bignotti, Eliana
    Todeschini, Paola
    Calza, Stefano
    Falchetti, Marcella
    Ravanini, Maria
    Tassi, Renata A.
    Ravaggi, Antonella
    Bandiera, Elisabetta
    Romani, Chiara
    Zanotti, Laura
    Tognon, Germana
    Odicino, Franco E.
    Facchetti, Fabio
    Pecorelli, Sergio
    Santin, Alessandro D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (05) : 944 - 953
  • [5] Indwelling Catheters for the Management of Refractory Malignant Ascites: A Systematic Literature Overview and Retrospective Chart Review
    Fleming, Nicole D.
    Alvarez-Secord, Angeles
    Von Gruenigen, Vivian
    Miller, Michael J.
    Abernethy, Amy P.
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2009, 38 (03) : 341 - 349
  • [6] Role of Cholesterol Determination in Ascitic Fluid Analysis
    Gerbes, Alexander L.
    Juengst, Dieter
    [J]. HEPATOLOGY, 2009, 50 (04) : 1320 - 1320
  • [7] Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer
    Gotlieb, WH
    Feldman, B
    Feldman-Moran, O
    Zmira, N
    Kreizer, D
    Segal, Y
    Elran, E
    Ben-Baruch, G
    [J]. GYNECOLOGIC ONCOLOGY, 1998, 71 (03) : 381 - 385
  • [8] Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer
    Harding, V.
    Fenu, E.
    Medani, H.
    Shaboodien, R.
    Ngan, S.
    Li, H. K.
    Burt, R.
    Diamantis, N.
    Tuthill, M.
    Blagden, S.
    Gabra, H.
    Urch, C. E.
    Moser, S.
    Agarwal, R.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 107 (06) : 925 - 930
  • [9] Antiangiogenic drugs in ovarian cancer
    Kumaran, G. C.
    Jayson, G. C.
    Clamp, A. R.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 100 (01) : 1 - 7
  • [10] Motherby H, 1999, DIAGN CYTOPATHOL, V20, P350, DOI 10.1002/(SICI)1097-0339(199906)20:6<350::AID-DC5>3.0.CO